In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Johnson & Johnson (JNJ – Research Report), with a price target of $185.00.
Josh Jennings has given his Buy rating due to a combination of factors that highlight Johnson & Johnson’s strategic advancements in the electrophysiology market. The company’s Biosense Webster division is actively evolving its strategy to regain market share by expanding its pulsed field ablation offerings and enhancing the interoperability of its CARTO mapping system. These efforts are supported by the introduction of new catheter form factors and the accumulation of improved safety data, which are expected to drive significant adoption in the U.S. market by 2026.
Furthermore, the leadership at Biosense Webster has outlined a clear path to reaccelerate growth by focusing on delivering faster, safer, and more effective therapies. This includes a commitment to generating robust clinical data to validate their performance across complex patient populations. The strategic initiatives, such as opening CARTO to competitive therapies and enhancing system interoperability, are designed to ensure Biosense Webster’s central role in future electrophysiology labs. These efforts are anticipated to align with Johnson & Johnson’s broader MedTech growth strategy, positioning the company for renewed leadership in the global market.
In another report released on April 17, Leerink Partners also maintained a Buy rating on the stock with a $169.00 price target.